Why Eli Lilly Topped the Market Today
Key Points
This market has a population of almost 60 million.
While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.
- 10 stocks we like better than Eli Lilly ›
Eli Lilly (NYSE: LLY) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided plenty of optimism for these types of drugs, which have been hotly popular for years now.
The popular pill
The product in question is Lilly's Foundayo, its first weight-loss pill (not to be confused with the company's Zepbound, an obesity treatment delivered via injection). On Monday, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved Foundayo for both weight management and type 2 diabetes.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
This made the U.K. the first European nation to green-light the pill for commercialization.
As in the U.S., however, Foundayo won't be the first weight-loss pill on that market. Similarly, the Wegovy pill from pharmaceutical industry rival Novo Nordisk is currently available to British patients; this was approved by the MHRA in June.
Big prizes for No. 2
While it's always a great advantage to be a first mover, I don't think Lilly will suffer much from finishing second in the race.
First, with its massive commercial infrastructure, it can allocate considerable resources to marketing its pill to local consumers. Second, the demand for obesity treatments is so strong that even a distant second-place developer can earn considerable sales in the U.K., with its population of nearly 60 million.
Finally, this is only Lilly's first approval in Europe, a vast market. Although the continent has less of a problem with obesity than the U.S., there is still quite a large addressable population of would-be patients.
With its size and sprawl, Lilly isn't only about weight-loss drugs. Regardless, this is an unambiguously positive development in this sustainably hot product category, so the British nod is quite a justifiable stock mover.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $399,832!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,374,595!*
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 10, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
